Select Location
What is your delivery location?
We need your delivery location to continue browsing
Select Location
We need your delivery location to continue browsing
Prescription Required
Hetero Healthcare Ltd
28 tablet
Sofosbuvir 400mg
Keep in cold place
Delivering To:
Overview
Sofosbuvir is the active ingredient of Sofovir 400mg Tablets. Hepatitis C virus (HCV) infection is treated with this direct-acting antiviral drug. In order to create a regimen that will successfully remove HCV from the body, this medication is frequently taken in combination with other antiviral medications. When compared to earlier treatments, the Sofovir 400mg Tablet has considerably reduced the length of time needed to treat HCV. It works well against a variety of hepatitis C virus genotypes. A wide variety of patients with varying HCV genotypes can benefit from this type of therapy due to its broad-spectrum action.
Hepatitis C
Treatment of hepatitis C virus (HCV) infection
Sofovir 400mg Tablet may cause some serious and unwanted side effects that require immediate medical attention; otherwise, it can also lead to a higher risk. Do not forget to discuss the risks and benefits of this medication with your doctor.
Insomnia
Nausea
Fainting
Neutropenia (low white blood cell count)
Chills and fever
Fatigue
Headache
Loss of appetite
Itching Joint pain
Do not crush, chew, or break the Sofovir Tablet. Take the same dose as prescribed by your healthcare provider. Please seek emergency medical attention in case of overdose.
Sofosbuvir tends to inhibit the Hepatitis C NS5B protein. It shows a high barrier to the development of resistance. Sofosbuvir is a prodrug of the Protide type, wherein the active phosphorylated nucleotide is granted with cell permeability and oral bioavailability. By hydrolysis of the carboxylate ester by either of the enzymes cathepsin A or carboxylesterase 1, Sofosbuvir is activated in the liver to the triphosphate GS-461203, which is followed by cleaving of the phosphoramidate by the enzyme histidine triad nucleotide-binding protein 1 (HINT1), with repeated phosphorylation. Dephosphorylation tends to create the inactive metabolite GS-331077. The half-life of Sofosbuvir is 0.4 hours, and the half-life of GS-331077 is 27 hours. Following a single 400 mg oral dose of Sofovir Tablet, 80% is normally excreted in the urine, 2.5% in expired air recovery, and 14% in feces.
Alcohol
unsafe
It is advisable not to consume alcohol while taking this medicine.
Pregnancy
consult your doctor
Do not take Sofovir 400mg Tablet without consulting the doctor, in case of pregnancy.
Breast Feeding
consult your doctor
Without a doctor's consultation, do not take this medicine if you're breastfeeding.
Driving
danger
It is advisable not to drive or operate heavy machinery, you may feel dizzy as one of the side effects of the medicine.
Kidney
caution
Do not take Sofovir 400mg Tablet without a doctor's consultation in case of kidney problems.
Liver
caution
Share your medical history with the doctor in case of liver disease before taking this medicine.
In case of a missed dose, take the medicine as soon as you remember. However, if it is already time for the next dose, do not take the previous dose. Skip it and take the scheduled dose. Also, tell your healthcare provider about the same.
Sofovir 400mg Tablet is an antiviral medicine. It is used with other medicines to treat chronic (long-lasting) hepatitis C virus (HCV) infection in adults.
Do not crush, chew, or break the tablet. Take it exactly as your healthcare provider tells you.
Store at room temperature (10-30°C). Keep it covered, and away from children, direct light, heat, and moisture.
There can be some side effects of Sofovir such as fever, headache, irritability, anemia, fatigue, and diarrhea. Nausea and skin rash. Kindly consult your healthcare provider if you experience these or any other side effects.
Do not drive or operate heavy machines in case you feel unwell after taking Sofovir 400mg.
Yes, senior patients can utilize 400 mg tablets of sofovir. Its usage is not prohibited by age alone. However, older patients may be more likely to have illnesses and to be taking more than one medicine, which can raise the possibility of drug interactions.
The main treatment for Sofovir 400mg Tablet is for people who already have hepatitis C. It can treat the infection and lower the viral load, but it doesn't directly prevent against developing hepatitis C or stopping its spread to other people. Using barrier techniques during intercourse, avoiding sharing needles or other drug paraphernalia, and taking steps to avoid blood-to-blood contact are all examples of safe behaviors that can prevent the spread of hepatitis C.
Yes, people with liver cirrhosis can take 400 mg tablets of sofovir. Patients with liver cirrhosis have proven its effectiveness and safety. Patients with severe liver disease, however, could need specialized treatment programs and close monitoring.
AbdelMagid, A.M. et al. (2024). Population pharmacokinetics of ledipasvir/sofosbuvir in pediatric patients with acute lymphoblastic leukemia: A modeling study. Clinical Therapeutics.
Mizokami,M., Liu, L.J., Fujiama, N., Littman, M., Yuan, J., Sekiya, T., Hedskog, C., Ng, L. J. (2024). Real‑world safety and effectiveness of ledipasvir/sofosbuvir for treating chronic HCV genotype 1 in a Japanese cohort. Journal Name. Retrieved from PubMed.
Treatment options to support the elimination of hepatitis C: an open‑label, factorial, randomised controlled non‑inferiority trial. (2025). The Lancet Gastroenterology & Hepatology.
Viral Hepatitis Study Group of the Turkish Society of Clinical Microbiology and Infectious Diseases. (2025). Evaluation of treatment response in chronic hepatitis C patients receiving sofosbuvir/velpatasvir/voxilaprevir: A multicenter real‑world experience from Türkiye. Viruses, 17(7), 931.
Viral Hepatitis Study Group of the Turkish Society of Clinical Microbiology and Infectious Diseases. (2025). Evaluation of treatment response in chronic hepatitis C patients receiving sofosbuvir/velpatasvir/voxilaprevir: A multicenter real‑world experience from Türkiye. Viruses, 17(7), 931.
Zhuang, L., Li, J., Zhang, Y., Ji, S., & Xing, H. (2025). Real‑world effectiveness of sofosbuvir/velpatasvir, glecaprevir/pibrentasvir, and sofosbuvir/velpatasvir/voxilaprevir against genotype 3 hepatitis C virus infection: A systematic review and meta‑analysis. Frontiers in Gastroenterology, 4, 1511150.
